FDA Approves Camzyos for Pediatric Obstructive Hypertrophic Cardiomyopathy

The FDA has expanded approval for Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in pediatric patients weighing at least 30 kg. This makes Camzyos the first FDA-approved therapy for oHCM in children, providing a new targeted treatment option for this population. This development significantly advances pediatric cardiovascular care.